Prescient Therapeutics Limited (PTX.AX)
Prescient Therapeutics Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Melbourne, VIC, AU. The stock last traded at $0.08, up 0.00% on the session, giving a market capitalisation of $88.3M. Its beta of 0.77 implies it has historically moved less than the broad market.
Prescient Therapeutics Limited (PTX.AX) is an Australian clinical-stage oncology firm dedicated to creating novel therapeutic agents for various cancer types. The company's primary experimental compound, PTX-200, is currently undergoing several clinical trials: Phase 2a for HER2-negative breast cancer, Phase 1B/2 for acute myeloid leukemia that has relapsed or is resistant to treatment, and Phase 1b for ovarian cancer that is recurrent, persistent, or resistant to platinum-based therapies. Additionally, PTX-100, a RhoA inhibitor, is being developed to target both blood cancers and solid tumors, specifically those characterized by Ras and RhoA genetic mutations. Prescient Therapeutics has also forged a strategic alliance with The University of Texas MD Anderson Cancer Center to advance the development of a blood cancer binder for their OmniCAR platform. Founded in Melbourne, Australia, in 1986, the company operated as Virax Holdings Limited until its rebranding as Prescient Therapeutics Limited in December 2014.
Prescient Therapeutics Limited is most often compared with the following Healthcare names: